Print  |  Font Size Change Font Size

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

What are the pros and cons of treatment with Methadone?


  • More than 30 years of experience in treating opioid addiction
  • Daily visits give more structure to patients who need it
  • Cost is usually less and may be calculated on a sliding scale based on income
  • The opportunity to meet many people who share the same addiction
  • Group counseling is often provided
  • It is an opioid so it is able to stop the withdrawal symptoms
  • It lasts for at least 24 hours
  • There is no legal limit to how many patients a methadone clinic can treat
  • Without a ceiling effect doses can be increased as the patient becomes tolerant


  • It is possible to continue to use illicit opioids while on methadone
  • Methadone treatment follows a strict protocol which makes some patients feel that they have no control over their own treatment
  • Shows up in urine testing for employment
  • Daily visits to the methadone clinic may be difficult for some patients who have jobs, especially when traveling distance is great.
  • Daily visits make overnight travel difficult for both business and pleasure
  • Some people find it difficult to overcome self-esteem issues in a clinic environment.

Back to FAQs

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release